MYO - Myomo Total Debt to Capital

Myomo, Inc (MYO) - corporate logo

The current price chart for Myomo, Inc. (MYO) illustrates the financial profile of the exoskeleton manufacturer, whose stable margins are supported by global distribution and reliable component suppliers. The total debt-to-equity ratio stands at 3.65 as the company captures a niche market for myoelectric devices designed for upper-limb functional restoration. The business is expanding its influence through strategic alliances with specialized medical centers, implementing robotic mobility recovery systems.

MYO: myomo.com Total Debt to Equity Ratio 07/04/2022 - 10/30/2026
Finished products of Myomo, Inc.

Operating cash flow dynamics directly impact the debt-to-equity ratio, reflecting the extent of the business's reliance on external creditors to maintain liquidity. For Myomo, Inc., which is scaling the deployment of robotic orthoses through clinic partnerships, the financial leverage of total debt-to-equity demonstrates a balance between investments in rehabilitation technologies and the company's financial stability.

Competitor analysis

Debt to Equity Boston Scientific Corporation|Edwards - Aggregate Debt to Equity|Total Debt to Capital RMD|PODD - Debt to Capital|Total Debt to Capital ZBH (Zimmer Biomet Corp)|COO - Total Debt to Equity Ratio|Align Technology - Total Debt to Capital|Total Debt to Capital Coefficient Globus Medical Inc GMED|TMDX: Total Debt to Capital|Alphatec Corp (ATEC) - Total Debt to Capital|Debt to Equity Artivion, Inc.|Debt to Equity ENOV|Total Debt to Capital IART|Total Debt to Capital Coefficient Establishment Labs Corp|Beta Bionics Corp - Total Debt to Equity Ratio|IRMD (IRADIMED Inc.) - Aggregate Debt to Equity|Embecta Corp. - Total Debt to Capital|Debt to Capital tandemdiabetes.com|AXGN: Total Debt to Capital|Debt to Equity Ratio SIBN|Total Debt to Equity Ratio OFIX|BVS: All Debt to Shareholders' Equity Ratio|Debt to Equity OrthoPediatrics Corp. (KIDS)|Total Debt to Equity Ratio treace.com TMCI|Total Debt to Capital SRTA (Strata Critical Medical)|Carlsmed, Inc. (CARL) - Debt to Capital|RxSight Corp - Total Debt to Capital|CLPT (ClearPoint Neuro, Inc.) - Debt to Equity Ratio|STXS: Total Debt to Capital|STIM - Total Debt to Capital Coefficient|SGHT (Sight Sciences) - Total Debt to Capital|Total Debt to Equity Ratio Orchestra BioMed Inc. (OBIO)|Total Debt to Capital ANIK|Total Debt to Capital InspireMD Inc. (NSPR)|Debt to Equity Jin Medical ZJYL|Vivani Medical Inc - Debt to Equity|XTNT: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio NMTC (NeuroOne)|MODD: Total Debt to Capital|Debt to Capital Envoy Medical Inc (COCH)|Debt to Equity Vivos Therapeutics|NVNO - Debt to Capital Ratio|Total Debt to Equity Ratio SINT (Sintx Technologies)|Total Debt to Capital Tenon Medical Inc. (TNON)|Total Debt to Capital LFWD (ReWalk Robotics Ltd)|Total Debt to Capital Coefficient Autonomix Medical Inc. (AMIX)|IVF - Debt to Equity|Aggregate Debt to Equity BBLG|Axonics (AXNX) - Debt to Equity|Total Debt to Equity Ratio BIOLASE Inc.|DYNT (Dynatronics Corp) - Total Debt to Capital|Debt to Capital Paragon 28 Corp FNA|Debt to Equity INVO Bioscience, Inc. (INVO)